Gonadotropin-releasing hormone agonists for endometriosis

Abstract

Condition tags

MeSH descriptors

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (34)

• A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis via openalex
• Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis via openalex
• Empirical therapy with leuprorelin acetate for endometriosis in the United States via openalex
• Endometriosis: cost estimates and methodological perspective via openalex
• Endometriosis in Clinical Practice via openalex
• Epidemiology of endometriosis-associated infertility via openalex
• Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis via openalex
• Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group via openalex
• Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis via openalex
• Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up via openalex
• Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group via openalex
• "Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis via openalex
• Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up via openalex
• Pathogenesis of endometriosis via openalex
• Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial via openalex
• Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain via openalex
• Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group via openalex
• Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain via openalex
• The role of add-back therapy in the United States via openalex
• Treatment of endometriosis via openalex
• Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin) via openalex
• Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis via openalex
• W2028587418 via openalex
• W4232174123 via openalex
• W2073640827 via openalex
• W2015747176 via openalex
• W2077115943 via openalex
• W2063184348 via openalex
• W1973283880 via openalex
• W1966343709 via openalex
• W2172287852 via openalex
• W2322133447 via openalex
• W2405398988 via openalex
• W2408619637 via openalex

Cited by (39)

• Endometriosis and ovulatory menstruation: beyond the Sampson principle 2025
• Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3) 2024
• Treatment of moderate-severe pain associated with early stage endometriosis; a consensus panel summary 2024
• Expectant, Medical, and Surgical Management of Ovarian Endometriomas 2023
• Medical Management of Ovarian Endometriomas: A Systematic Review and Meta-analysis 2023
• Treatment of moderate-severe pain associated with early stage endometriosis; a consensus panel summary 2023
• Assessment of Two Formulations of Triptorelin in Chinese Patients with Endometriosis: A Phase 3, Randomized Controlled Trial 2022
• GnRH agonists in the treatment of symptomatic endometriosis: a review 2022
• Estrogen receptor beta promotes endometriosis progression by upregulating CD47 expression in ectopic endometrial stromal cells 2022
• Puberty in the Female and Its Disorders 2021
• New Therapeutics in Endometriosis: A Review of Hormonal, Non-Hormonal, and Non-Coding RNA Treatments 2021
• Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial 2020
• Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study 2019
• Relationships between vitamin D receptor genetic polymorphisms and endometriosis in Korean women 2019
• GONADOTROPIN-RELEASING HORMONE AGONISTS IN ENDOMETRIOSIS TREATMENT AND IN VITRO FERTILIZATION 2018
• Long-Term Effects of Gonadotropin-Releasing Hormone Agonists and Add-Back in Adolescent Endometriosis 2018
• Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist 2018
• A comparison of two months pretreatment with GnRH agonists with or without an aromatase inhibitor in women with ultrasound-diagnosed ovarian endometriomas undergoing IVF 2018
• Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist 2017
• Adenomyosis in climacteric women 2015
• Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist: Results from a Phase 2, Randomized Controlled Study 2015
• Possible association of maternal factors with the higher risk of isolated true undescended testis: A population-based case-control study 2014
• Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density 2014
• Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study 2013
• Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study 2013
• Oral continuous combined 0.5 mg estradiol valerate and 5 mg dydrogesterone as daily add-back therapy during post-operative GnRH agonist treatment for endometriosis in Chinese women 2013
• Quality of life according to add-back therapy during GnRH agonist treatment in endometriosis patients 2012
• Endometriosis and Chronic Pelvic Pain 2012
• Seven ways to preserve female fertility in patients with endometriosis 2012
• The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis 2012
• Acupuncture for pain in endometriosis 2011
• Endometriosis: Current and Emerging Therapies 2011
• Prävalenz von Depressionen und Angststörungen und ihre Einflussfaktoren bei Frauen mit Endometriose 2011
• Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? 2010
• Peritoneal vascular density assessment using narrow-band imaging and vascular analysis software, and cytokine analysis in women with and without endometriosis 2009
• Selective Inhibition of Prostaglandin E2 Receptors EP2 and EP4 Induces Apoptosis of Human Endometriotic Cells through Suppression of ERK1/2, AKT, NFκB and β-CATENIN Pathways and Activation of Intrinsic Apoptotic Mechanisms 2009
• Acupuncture for pain in endometriosis 2009
• Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms 2009
• Gonadotropin-releasing hormone agonists for endometriosis 2008

Source provenance

europepmc

last seen: 2026-10-15T06:08:49.021275+00:00

openalex

last seen: 2026-06-10T17:14:06.276822+00:00

pubmed

last seen: 2026-10-08T21:05:43.569505+00:00

unpaywall

last seen: 2026-10-15T06:24:24.424788+00:00